Antimicrobial activity of pomegranate fruit constituents against drug-resistant Mycobacterium tuberculosis and β-lactamase producing Klebsiella pneumoniae

Pharmaceutical Biology

Volumn 53, Issue 10, 2015, Pages 1474-1480

  Dey, Diganta ^a,b   Ray, Ratnamala ^b   Hazra, Banasri ^a  

^a JADAVPUR UNIVERSITY   (India)

^b Department of Microbiology   (India)

Author keywords

Antitubercular; Caffeic acid; Carbapenemase; Ellagic acid; Epigallocatechin 3 gallate; Extended spectrum lactamase; Punica granatum Linn.; Quercetin

Indexed keywords

CAFFEIC ACID; CIPROFLOXACIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; POMEGRANATE EXTRACT; QUERCETIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; PLANT EXTRACT; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RESPIRATORY TRACT INFECTION; DRUG EFFECTS; FRUIT; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; LYTHRACEAE; MULTIDRUG RESISTANCE; PHYSIOLOGY;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE; LYTHRACEAE; MYCOBACTERIUM TUBERCULOSIS; PUNICA GRANATUM;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRUIT; HUMANS; KLEBSIELLA PNEUMONIAE; MYCOBACTERIUM TUBERCULOSIS; PLANT EXTRACTS; PUNICACEAE;

EID: 84939190423     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.986687     Document Type: Article

References (26)

1. Arnold RS, Thom KA, Sharma S, et al. (2011). Emergence of Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. South Med J 104:40-5.
2. Baell JB, Holloway GA. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-40.
3. Biswas T, Resto-Roldán E, Sawyer SK, et al. (2013). A novel nonradioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG. Nucleic Acids Res 41:e56.
4. Clinical and Laboratory Standards Institute. (2013). Performance Standards for Antimicrobial Susceptibility Testing; Twenty Third Informational Supplement. Wayne: CLSI.
5. Cockerill III FR. (1998). Conventional and genetic laboratory tests used to guide antimicrobial therapy. Mayo Clin Proc 73:1007-21.
6. Collee JG, Fraser AG, Marmion BP, Simmons A. eds. (1996). Mackie and McCartney Practical Medical Microbiology. London: Churchill Livingstone.
7. Correa L, Martino MD, Siqueira I, et al. (2013). A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 13:80.
8. Dai J, Mumper RJ. (2010). Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. Molecules 15:7313-52.
9. Davies J, Davies D. (2010). Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-33.
10. Dey D, Debnath S, Hazra S, et al. (2012). Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extendedspectrum b-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram negative bacilli. Food Chem Toxicol 50:4302-9.
11. Dey D, Ray R, Hazra B. (2014). Antitubercular and antibacterial activity of quinonoid natural products against multi-drug resistant clinical isolates. Phytother Res. 28:1014-21.
12. Glaser J, Schultheis M, Hazra S, et al. (2014). Antileishmanial lead structures from nature: Analysis of structure-activity relationships of a compound library derived from caffeic acid bornyl ester. Molecules 19:1394-410.
13. Gradisar H, Pristovsek P, Plaper A, Jerala R. (2007). Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem 50:264-71.
14. Jurenka J. (2008). Therapeutic applications of pomegranate (Punica granatam L.): Review. Altern Med Rev 13:128-44.
15. Kang C-I, Song J-H. (2013). Antimicrobial resistance in Asia: Current epidemiology and clinical implications. Infect Chemother 45:22-31.
16. Knothe H, Shah P, Krcmery V, et al. (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11:315-17.
17. Kolyva AS, Karakousis PC. (2012). Old and new TB drugs: Mechanisms of action and resistance. In: Cardona P-J, ed. Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance. Europe: InTech, 209-32.
18. Naz S, Siddiqi R, Ahmad S, et al. (2007). Antibacterial activity directed isolation of compounds from Punica granatum. J Food Sci 72:341-5.
19. Plaper A, Golob M, Hafner I, et al. (2003). Characterisation of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun 306:530-6.
20. Scalbert A, Manach C, Morand C, et al. (2005). Polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45:287-306.
21. Sharma SK, Kumar G, Kapoor M, Surolia A. (2008). Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis. Biochem Biophys Res Commun 368:12-17.
22. Silva T, Oliveira C, Borges F. (2014). Caffeic acid derivatives, analogs and applications: A patent review (2009-2013). Expert Opin Ther Pat 24:1257-70.
23. Suriyanarayanan B, Shanmugam K, Santhosh RS. (2013). Synthetic quercetin inhibits mycobacterial growth possibly by interacting with DNA gyrase. Rom Biotechnol Lett 18:1587-93.
24. Wong SY, Grant IR, Friedman M, et al. (2008). Antibacterial activities of naturally occurring compounds against Mycobacterium avium subsp. paratuberculosis. Appl Environ Microbiol 74:5986-90.
25. World Health Organization. (2012). Global tuberculosis report (WHO/HTM/TB/2012.6.). Geneva, Switzerland: WHO [Online]. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf [last accessed 17 Nov. 2014].
26. Zhang YM, Rock CO. (2004). Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J Biol Chem 279:30994-1001.